

> 定義


# LYMPHOMA

## 定義

• Malignant disorder of lymphoid cells that reside predominantly in lymphoid tissues

• Generally characterized as **Hodgkin lymphoma** (HL) or **non-Hodgkin lymphoma** (NHL)

## 臨床表現

• Lymphadenopathy (nontender)

### HL: Reed-Sternberg (RS) **cells;** superficial (usually **cervical**/**supraclavicular**) ± mediastinal LAN; **nodal** disease with **orderly**, **anatomic spread** to adjacent nodes

### NHL:** diffuse; nodal and/or extranodal** disease with **noncontiguous spread;** symptoms reflect involved sites (abdominal fullness, bone pain)

• Constitutional (“B”) symptoms: **fever** (>38°), drenching **sweats**, ↓ **weight** (>10% in 6 mo)

**HL:** periodic, recurrent “Pel-Ebstein” fever; 10–15% have pruritus; ~35% “B” symptoms

**NHL:** “B” symptoms vary between subtypes, ~15–50%

Diagnostic and staging evaluation

• Physical exam: lymph nodes, liver/spleen size, Waldeyer’s ring, testes (~1% of NHL), skin

• Pathology: **excisional lymph node bx** (not FNA b/c need surrounding architecture) with immunophenotyping and cytogenetics; **BM** bx or **PET** (except in HL 臨床stage IA/IIA with favorable features or CLL by flow); LP if CNS involvement clinically suspected

• Lab tests: CBC, BUN/Cr, LFTs, ESR, LDH, UA, Ca, alb; ✔ HBV & HCV (and must ✔ HBsAg & anti-HBc if planning rituximab Rx, b/c can lead to HBV reactivation); consider HIV, HTLV, & EBV serologies and connective tissue diseases autoAbs

• Imaging: PET-CT scans b/c CT alone does **not** reliably detect spleen/liver involvement (espec. in HL, DLBCL). PET response to Rx can be prognostic & possibly guide Rx (_NEJM_ 2015;372:1598 & 2016;374:2419). Head CT/MRI _only_ if neurologic symptoms.

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><p><b>Ann Arbor Staging System with Cotswolds Modifications</b></p></td></tr><tr><td><p><b>Stage</b></p></td><td><p><b>Features</b></p></td></tr><tr><td><p>I</p></td><td><p>Single lymph node (LN) region</p></td></tr><tr><td><p>II</p></td><td><p>≥2 LN regions on the same side of the diaphragm</p></td></tr><tr><td><p>III</p></td><td><p>LN regions on both sides of the diaphragm</p></td></tr><tr><td><p>IV</p></td><td><p>Disseminated involvement of one or more extralymphatic organs</p></td></tr><tr><td colspan="2"><p>Modifiers: A = no symptoms; B = fever, night sweats or weight loss; X = bulky disease = greatest transverse diam. of mediastinal mass/max diam. of chest wall &gt;1/3 on CXR or &gt;10 cm if in abd; E = involves single contiguous extranodal site; H = hepatic; S = splenic</p></td></tr></tbody></table>

HODGKIN LYMPHOMA (HL) (_Am J Hematol_ 2018;93:704)

流行病學 and risk factors

• ~9,000 cases/y; bimodal distribution (15–35 & >50 y); ↑ ♂; role of EBV in subsets of HL, esp. immunocompromised patients (eg, HIV)

Pathology

• Affected nodes show RS cells (<1%) in background of non-neoplastic inflammatory cells

• Classic RS cells: bilobed nucleus & prominent nucleoli with surrounding clear space (“owl’s eyes”). RS cells are **clonal B-cells:** CD15+, CD30+, CD20– (rarely +).

<table><colgroup><col> <col> <col></colgroup><tbody><tr><td colspan="3"><p><b>WHO Histologic Classification of Classical HL</b></p></td></tr><tr><td><p><b>Nodular sclerosis</b></p></td><td><p>60–80%</p></td><td><p>Collagen bands; frequent mediastinal LAN; young adults; female predominance; usually stage I or II at dx</p></td></tr><tr><td><p><b>Mixed cellularity</b></p></td><td><p>15–30%</p></td><td><p>Pleomorphic; older age; male predominance; ≥50% stage III or IV at presentation; intermediate prognosis</p></td></tr><tr><td><p><b>Lymphocyte rich</b></p></td><td><p>5%</p></td><td><p>Abundant normal-appearing lymphocytes; mediastinal LAN uncommon; male predominance; good prognosis</p></td></tr><tr><td><p><b>Lymphocyte depleted</b></p></td><td><p>&lt;1%</p></td><td><p>Diffuse fibrosis and large numbers of RS cells; older, male patients; disseminated at dx; seen in HIV; worst prognosis</p></td></tr></tbody></table>

• **Nonclassical** (5%): nodular lymphocyte predominant (NLP); involves peripheral LN

80% present in stages I–II and Rx can be RT alone or combination chemo + RT with 4-yr progression-free survival 88% and overall survival 96% (_JCO_ 2008;26:434)

Consider rituximab because most 正常P RS cells are CD20+

Stages III–IV treated with combination chemo (see below)

治療 (_Lancet_ 2012;380:836)

• **Stages I–II: ABVD** (doxorubicin, bleomycin, vinblastine, dacarbazine) ± RT if favorable disease

• **Stages III–IV: ABVD** × 6 cycles (can omit B if PET ⊖ after 2 cycles _NEJM_ 2016;374:2419; brentuximab (anti-CD30) may replace bleo but more toxic (_NEJM_ 2018;378:331); or **escalated BEACOPP** (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone); add RT for select 病人 as consolidation

• Refractory/relapsed disease: salvage chemo + auto HSCT ± RT

brentuximab vedotin post-ASCT yields some long-term remissions (_Blood_ 2016;128:1562)

PD1/PDL1 blockade (eg, pembrolizumab or nivolumab) (_NEJM_ 2015;372:311)

• Late effects include ↑ risk for:

**Second cancers:** ~4.6× risk for up to 40 y (_NEJM_ 2015;373:2499)

_breast_ (if RT), ∴ annual screening at age 40 or 8–10 y post RT

_lung_, efficacy of screening chest CT remains a topic of research

_acute leukemia/MDS; NHL_

### Cardiac disease (if RT or anthracycline), ? role of echo/stress at 10 y (controversial)

### Pulmonary toxicity (if bleomycin)

### Hypothyroidism (if RT), ∴ annual TSH (if neck RT)

<table><colgroup><col> <col> <col></colgroup><tbody><tr><td colspan="3"><p><b>International Prognostic Score (IPS</b>) <span>(</span><span><i>JCO</i></span> <span>20</span><span>1</span><span>2;30:3383)</span></p></td></tr><tr><td><p><b>Negative Prognostic Indicators</b></p></td><td><p><b>Total # of Indicators</b></p></td><td><p><b>5-y PFS</b></p></td></tr><tr><td><p>Albumin &lt;4 g/dL; Hb &lt;10.5 g/dL</p><p>Male; Age &gt;45 y</p><p>Stage IV</p><p>WBC ≥15k/µL</p><p>Lymphocytes &lt;600/µL or &lt;8% of differential</p></td><td><p>0</p><p>1</p><p>2</p><p>3</p><p>4</p><p>≥5</p></td><td><p>88%</p><p>84%</p><p>80%</p><p>74%</p><p>67%</p><p>62%</p></td></tr></tbody></table>

NON\-HODGKIN LYMPHOMA (NHL)

流行病學 and risk factors

• ~70,000 new cases/y; median age at dx ~65 y; ♂ predominance; 85% B-cell origin

• Associated conditions: immunodeficiency (eg, HIV, posttransplant); autoimmune

disorders (eg, Sjögren’s, RA, SLE); infection (eg, EBV, HTLV-I, _H. pylori_)

• Burkitt lymphoma: (1) endemic or African (jaw mass, 80–90% EBV-related); (2) sporadic or American (20% EBV-related); (3) HIV-related

![](images/00093.jpeg)

治療 (_Lancet_ 2017;390:298)

• 治療 and prognosis determined by histopathologic classification rather than stage

• Rituximab (anti-CD20; _NEJM_ 2012;366:2008) if CD20+

• **Indolent:** generally no cure (except allo HSCT), goal sx mgmt (bulky dis, cytopenia, “B” sx)

Initial: RT if localized, rituximab + chemo (bendamustine, CVP, fludarabine), ibrutinib. Obinutuzumab (anti-CD20) + chemo with obinutuzumab maintenance ↑ PFS but ↑ toxicity (_NEJM_ 2017;377:1331)

Maintenance: rituximab in indolent, aggressive, and relapsed disease (_Lancet_ 2011;377:42)

Hairy cell: cladribine; oral BRAF inhibitor if relapsed/refractory (_NEJM_ 2015;373:1733)

Gastric MALT: can cure by treating _H. pylori_ if ⊕, RT for relapsed/refractory

• **Aggressive:** goal is cure (_Am J Hematol_ 2019;94:604), 治療 depends on subtype

### R-CHOP (rituximab, cyclophosphamide, doxorubicin = hydroxydaunorubicin, vincristine = Oncovin, prednisone) (_NEJM_ 2002;346:235 & 2008;359:613) DLBCL 10-y PFS = 45%; overall survival = 55% (_Blood_ 2010;116:2040)

\+ **Radiation** for localized or bulky disease

Consider **CNS prophylaxis** with intrathecal or systemic high-dose methotrexate if paranasal sinus, testicular, breast, periorbital, paravertebral, or bone marrow involved; ≥2 extranodal sites + ↑ LDH may also warrant

Refractory/relapsed disease: salvage chemo; high-dose chemo + auto-HSCT (_JCO_ 2001;19:406); allo-HSCT if beyond 2nd relapse (_JCO_ 2011;29:1342)

### CAR-T (qv): axicabtagene or tisagenlecleucel (_NEJM_ 2017;377:2531 & 2545)

Mantle cell: ibrutinib for relapsed/refractory disease (_Lancet_ 2016;387:770)

• **Highly aggressive**

**Burkitt:** dose-adjusted EPOCH-R (_NEJM_ 2013;369:1915) or CODOX-M/IVAC (cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate, ifosfamide, etoposide, high-dose cytarabine rituximab) (_Blood_ 2008;112:2248)

All 病人 receive CNS prophylaxis & tumor lysis syndrome prophylaxis

Addition of rituximab improves EFS (_Lancet_ 2016;387:2402)

### Lymphoblastic lymphoma (B or T cell): treated like ALL (see “Acute Leukemia”)

**High-grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6:** previously “double-/triple-hit” lymphoma, assoc. with poor prognosis

Prognosis

• Indolent: typically incurable, but long median survival

• Aggressive: ↑ chance of cure, but overall worse prognosis

<table><colgroup><col> <col> <col></colgroup><tbody><tr><td colspan="3"><p><b>Follicular Lymphoma International Prognostic Index (FLIPI)</b> <span>(</span><span><i>Blood</i></span> <span>2004;</span><span>1</span><span>04:</span><span>1</span><span>258)</span></p></td></tr><tr><td colspan="3"><p>Factors: age &gt;60, stages III/IV, Hb &lt;12 g/dL, &gt;4 nodal areas, LDH &gt;nl</p></td></tr><tr><td><p><b># Factors</b></p></td><td><p><b>5-y Overall Survival</b></p></td><td><p><b>10-y Overall Survival</b></p></td></tr><tr><td><p>0–1</p></td><td><p>90%</p></td><td><p>71%</p></td></tr><tr><td><p>2</p></td><td><p>78%</p></td><td><p>51%</p></td></tr><tr><td><p>≥3</p></td><td><p>52%</p></td><td><p>35%</p></td></tr></tbody></table>

<table><colgroup><col> <col> <col></colgroup><tbody><tr><td colspan="3"><p><b>International Prognostic Index (IPI) for Aggressive NHL</b> <span>(</span><span><i>Blood</i></span> <span>2007;</span><span>1</span><span>09:</span><span>1</span><span>857)</span></p></td></tr><tr><td colspan="3"><p>Factors: age &gt;60, stage III/IV, ≥2 extranodal sites, performance status ≥2, LDH &gt; 正常</p></td></tr><tr><td><p><b># Factors</b></p></td><td><p><b>Complete Response</b></p></td><td><p><b>5-y Overall Survival</b></p></td></tr><tr><td><p>0–1</p></td><td><p>87%</p></td><td><p>73%</p></td></tr><tr><td><p>2</p></td><td><p>67%</p></td><td><p>51%</p></td></tr><tr><td><p>3</p></td><td><p>55%</p></td><td><p>43%</p></td></tr><tr><td><p>4–5</p></td><td><p>44%</p></td><td><p>26%</p></td></tr><tr><td colspan="3"><p><b>Revised IPI Prognosis in Patients Rx’d with CHOP-R</b></p></td></tr><tr><td><p><b>Factors</b></p></td><td><p><b>% at Dx</b></p></td><td><p><b>4-y Overall Survival</b></p></td></tr><tr><td><p>0</p></td><td><p>10%</p></td><td><p>94%</p></td></tr><tr><td><p>1–2</p></td><td><p>45%</p></td><td><p>79%</p></td></tr><tr><td><p>3–5</p></td><td><p>45%</p></td><td><p>55%</p></td></tr></tbody></table>

HIV-associated NHL (_Blood_ 2006;107:13)

• HIV ⊕ imparts 60–100× relative risk

• NHL is an AIDS-defining malignancy along with Kaposi’s, cervical CA, anal CA

• Concurrent HAART & chemotherapy likely provide survival benefit

• DLBCL & immunoblastic lymphoma (67%): CD4 <100, EBV-associated Treat as immunocompetent (CHOP-R), but avoid rituximab if CD4 <100 Alternative regimens include R-EPOCH (etop, pred, vincristine, cyclophos, doxorubicin)

• Burkitt lymphoma (20%): can occur with CD4 >200 Treat as immunocompetent; prognosis is not significantly worse

• Primary CNS lymphoma (16%): CD4 <50, EBV-associated (also seen in 病人 without HIV). Rx with high-dose MTX-based regimen + steroids ± temozolomide ± RT, consider auto HSCT.

• Primary effusion lymphoma (<5%): HHV8 driven; also can be seen in other immuno- supp. 病人 such as s/p solid organ transplant or with chronic HBV. Treat with standard CHOP (often CD20–) or consider EPOCH, overall poor prognosis.

SMALL LYMPHOCYTIC LYMPHOMA (SLL) OR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

定義 (_NEJM_ 2005;352:804; _Blood_ 2008;111:5446)

• Monoclonal accumulation of functionally incompetent mature B lymphocytes

• CLL (>5000/µL malignant cells) & small lymphocytic lymphoma (SLL; <5000/µL malignant cells, with + LAN ± splenomegaly) classified as same disease

• Monoclonal B lymphocytosis: resembles but does not meet CLL criteria, observe

流行病學 and risk factors

• ~15,000 new cases/y; median age at dx is 71 y; most common adult leukemia

• ↑ incidence in 1st\-degree relatives; no known association with radiation, chemicals, drugs

臨床表現

• Symptoms: **often asx** & identified when CBC reveals lymphocytosis; 10–20% 表現為 fatigue, malaise, night sweats, weight loss (ie, lymphoma “B” sx)

• Signs: **lymphadenopathy** (80%) and **hepatosplenomegaly** (50%)

• **Autoimmune hemolytic anemia** (AIHA) (~10%) or **thrombocytopenia** (ITP) (~1–2%)

• Hypogammaglobulinemia ± neutropenia → ↑ susceptibility to **infections**

• Bone marrow failure in ~13%; monoclonal gammopathy in ~5%

• Aggressive transformation: ~5% develop **Richter’s syndrome** = transformation into high-grade lymphoma (usually DLBCL) and sudden 臨床deterioration

Diagnostic evaluation (see “Lymphoma” for general approach)

• **Peripheral smear: lymphocytosis** (>5000/µL, mature-appearing small cells) “**smudge**” cells from damage to 異常 lymphs from shear stress of making blood smear

• **Flow cytometry: clonality** with dim surface Ig (sIg); CD5+, CD19+, CD20(dim), CD23+. CD38+ or ZAP70+ a/w unmutated Ig variable heavy chain region & worse prognosis.

• **Bone marrow:** normo- or hypercellular; infiltrated with small B-cell lymphocytes (≥30%)

• **Lymph nodes:** infiltrated with small lymphocytic or diffuse small cleaved cells = SLL

• **Genetics:** del 11q22-23 & 17p13 unfavorable; trisomy 12 neutral; del 13q14 and mut _IgVH_ favorable. Nine significantly mutated genes, including _TP53, NOTCH1_, _MYD88_, and _SF3B1._ Key role for spliceosome mutations (_NEJM_ 2011;365:2497; _JCI_ 2012;122:3432).

![](images/00094.jpeg)

治療 (_Lancet_ 2018;391:1524)

• No 治療 unless: Rai stage III/IV, Binet stage C, disease-related sx, progressive disease, AIHA or ITP refractory to steroids, recurrent infections

• **First-line:** ibrutinib (inhibits Bruton’s tyrosine kinase \[BTK\], which is found in B cells; _NEJM_ 2015;375:25 & 2018;379:2517), risk of AF, HTN & bleeding (avoid if on warfarin), PNA, ILD

• Other options: purine analogues: fludarabine (“F”), pentostatin (“P”);

alkylating agents: cyclophosphamide (“C”), bendamustine (“B”);

± anti CD20 (**rituximab**, “R”; ofatumumab; obinutuzumab) or CD52 (alemtuzumab)

ibrutinib + obinutuzumab ↑ PFS vs. chlorambucil + obinutuzumab (_Lancet Oncol_ 2019;20:43)

venetoclax + obinutuzumab ↑ PFS vs. chlorambucil + obinutuzumab (_NEJM_ 2019;380:2225)

ibrutinib + venetoclax under study as 1st\-line Rx: 88% with CR (_NEJM_ 2019;380:2095)

• **Refractory:** venetoclax (α-BCL2; _NEJM_ 2018;378:1107), acalabrutinib (BTK inhibitor; _NEJM_ 2016;374:323), idelalisib (PI3K inhibitor; _NEJM_ 2014;370:997)

• 17p- or _TP53_ mutation: venetoclax, idelalisib, or ibrutinib ± rituximab (_Lancet Oncol_ 2014;10:1090), consider allo-HSCT with reduced intensity conditioning

• Supportive care & managing complications: PCP, HSV, VZV prophylaxis; CMV monitoring for 病人 receiving anti-CD52; AIHA/ITP → steroids; recurrent infections → IVIg

Prognosis (_NEJM_ 2004;351:893; _JCO_ 2006;24:4634)

• Survival varies substantially. Median overall survival ~10 y (_Am J Hematol_ 2011;12:985)

• Favorable prognosis: 13q14 deletion (~50% of CLL cases)

• Poor prognosis:

unfavorable cytogenetics: eg, 17p- or _TP_53 mutation (_JCO_ 2010;28:4473), IgH translocations

unmutated (<2% c/w germline) _IgVH_ gene (<8–10 y vs. >20–25 y if mutated)

high (>20–30%) Zap-70 expression (part of T cell receptor; correlated with unmutated _IgVH_)

CD38 >30% or CD49d <30%: correlated with unmutated _IgVH_ (_Blood_ 2008;111:865)

higher β2\-microglobulin levels (correlate with disease stage and tumor burden)
